WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage

Rhea-AI Summary

WeightWatchers (NASDAQ: WW) launched RxFlexFund on October 17, 2025, a new employer benefit model to expand GLP-1 access by combining direct manufacturer pricing, employer subsidies, and WeightWatchers clinical and behavioral support.

Employers pay for WeightWatchers Clinic and subsidize medication costs at a set rate of 25%–75%. Members receive FDA‑approved GLP‑1 prescriptions with obesity‑trained clinicians, nutrition and behavior programs, and registered dietitians. Company cites a 20% reduction in annual healthcare expenses linked to weight loss and a reported 46% boost in work‑related quality of life in a 6‑month trial (n=180).

Positive

• Employer subsidy range of 25%–75% for GLP-1 medication costs
• Access to direct manufacturer pricing for employers
• 46% reported increase in work-related quality of life (6‑month trial, n=180)
• Company cites 20% reduction in annual healthcare expenses after weight loss

Negative

• Employers must pay for WeightWatchers Clinic plus a 25%–75% share of drug costs
• Clinical outcomes cited include a 6‑month trial (n=180) with manuscript currently under review

Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the launch of WeightWatchers RxFlexFund™, a first-of-its-kind solution that combines direct pricing from pharmaceutical manufacturers with flexible employer subsidy coverage for GLP-1s, integrated with WeightWatchers’ full-spectrum behavioral and clinical support.

With WeightWatchers RxFlexFund, employers cover the cost of WeightWatchers Clinic and contribute a set percentage of medication costs, ranging from 25% to 75%, to help offset the impact of GLP-1 medication costs for their employees. Through this solution, employers also gain access to direct manufacturer pricing, providing transparent, competitive costs.

Members of WeightWatchers RxFlexFund receive WeightWatchers’ holistic model of care, including access to FDA-approved GLP-1 medications under the care of obesity-trained clinicians, WeightWatchers’ wraparound behavior change program with nutritional support designed for those taking GLP-1s, and access to registered dietitians and fitness specialists. The ease of WeightWatchers Clinic means members receive prescriptions and refills, along with the support needed to increase adherence and minimize potential medication side effects to help maximize health outcomes.

“Employers are at a crossroads when it comes to GLP-1 benefits," said Scott Honken, PharmD, Chief Commercial Officer of WeightWatchers. “Our clients consistently tell us that costs are rising and traditional coverage models leave little flexibility or opportunity for innovation. WeightWatchers RxFlexFund changes that by giving employers a clear, predictable way to offer GLP-1 access without navigating complex rebates or unpredictable add-on expenses. It opens the door to broader access while delivering meaningful clinical results and protecting the bottom line.”

Annual healthcare expenses are reduced by 20% when individuals with at least one chronic condition are able to lose weight and move from having obesity to overweight.¹ As noted in WeightWatchers for Business 2025 Annual Results Report, the WeightWatchers Clinic program positively impacts whole person health, including work life, with recent clinical trial participants reporting a 46% boost in work-related quality of life². This has the potential to produce significant ripple effects, including increased productivity, higher job satisfaction, improved employee engagement, and reductions in absenteeism.

“Weight management affects both employee health and overall business performance,” said Dr. Kim Boyd, Chief Medical Officer of WeightWatchers. “As healthcare costs continue to rise, employers are often forced to choose between affordability and access. WeightWatchers RxFlexFund reimagines the equation by introducing a new model to expand access to GLP-1 treatment to those who would benefit while maintaining medical responsibility and long-term behavior change support, reflecting our leadership in delivering improved outcomes for individuals and businesses.”

By expanding access, improving convenience and controlling costs, WeightWatchers RxFlexFund from WeightWatchers for Business allows more people to get the support they need to live healthier lives. To learn more about WeightWatchers RxFlexFund, connect with the WeightWatchers team at HLTH at the WW Pickle & Social Club or visit: business.weightwatchers.com/rxflexfund.

ABOUT WEIGHTWATCHERS
WeightWatchers is the global leader in science-backed weight management, offering an integrated support system that combines scientific expertise and human connection. With more than 60 years of experience, WeightWatchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions, medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has surrounded its members with the support they need to reach and sustain their goals, wherever they are on their journey. Members can access these solutions directly, or through WeightWatchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, WeightWatchers offers a proven path forward, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

————————————
¹ Thorpe K, Toles A, Shah B, Schneider J, Bravata DM. Weight Loss-Associated Decreases in Medical Care Expenditures for Commercially Insured Patients With Chronic Conditions. J Occup Environ Med. 2021 Oct
² Based on a 6-month clinical trial (n=180) of individuals with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program. Heinberg et al. Psychosocial Outcomes in a Telemedicine and Long-Acting Incretin Specific Behavioral Intervention. Manuscript under review. Funded by WW International, Inc.

For media inquiries, please contact:
Kelsey Merkel
media@ww.com

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

FAQ

What is WeightWatchers RxFlexFund announced on October 17, 2025 (WW)?

RxFlexFund is an employer benefit model combining direct manufacturer pricing, employer subsidies for GLP-1s, and WeightWatchers clinical and behavioral support.

How much of GLP-1 medication costs will employers cover under WW RxFlexFund?

Employers contribute a set percentage of medication costs ranging from 25% to 75%.

Does WW RxFlexFund include clinical care and prescriptions for GLP-1s?

Yes. Members receive FDA‑approved GLP-1s under obesity‑trained clinicians via WeightWatchers Clinic, plus nutrition and behavior support.

What cost savings or outcomes does WeightWatchers cite for RxFlexFund?

Company cites a 20% reduction in annual healthcare expenses tied to weight loss and a 46% boost in work-related quality of life in a 6‑month trial (n=180).

How can employers learn more or enroll in WW RxFlexFund (WW)?

Employers can connect with WeightWatchers at HLTH or visit business.weightwatchers.com/rxflexfund for details.

Are the clinical trial results for WeightWatchers GLP-1 companion program published?

The cited 6‑month trial (n=180) is noted as a manuscript under review and was funded by WeightWatchers.